DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a blank check company that completed its initial public offering in 2017, with a final prospectus filed on Form 424B4 with the SEC on June 21, 2017. Targeting the healthcare and precision medicine sector, the vehicle focused specifically on molecular diagnostics and dermatology, a niche within non-invasive genomic skin analysis. The SPAC subsequently pursued a business combination, with the resulting entity developing genomic tests for skin conditions, including non-invasive melanoma screening. DMTK traded on the Nasdaq following the de-SPAC transaction. Researchers and investors seeking complete filing history, deal timelines, and financial metrics for DMTK can sign up for full data access on SpacDesk.